



## **ProteoTech to Present at 9<sup>th</sup> International Conference for Alzheimer's and Parkinson's Disease – Prague, Czech Republic, March 11-15, 2009**

**Kirkland, WA, March 9, 2009/PR Newswire-** ProteoTech Inc. announced today that both Dr. Alan D. Snow, Chairman, President & CSO, and Dr. Luke Esposito, Director of *In Vitro* Screening, will present at the 9<sup>th</sup> International Conference for Alzheimer's and Parkinson's Diseases, to be held in Prague, Czech Republic, March 11-15, 2009. On Sunday March 15, Dr. Alan D. Snow will give an oral presentation discussing promising results pertaining to ProteoTech's current Phase 1A human clinical trial with the small molecule Exebryl-1® for the treatment of mild-to-moderate Alzheimer's disease. Dr. Snow's talk is entitled: "Exebryl-1®: A Novel Small Molecule Currently in Human Clinical Trials as a Disease-Modifying Drug for the Treatment of Alzheimer's Disease."

Dr. Luke Esposito on Saturday March 14-Sunday March 15 will present during the "Synucleinopathies" poster session. Dr. Esposito's presentation is entitled: "Synuclere™: Development of a Novel Small Molecule that Effectively Reduces Alpha-Synuclein Aggregation and Improves Motor Dysfunction". Synuclere™ is a novel small molecule developed by ProteoTech that looks promising as a future disease-modifying treatment for Parkinson's disease and related disorders. ProteoTech's work in Parkinson's disease was partially funded by a LEAPS award from The Michael J. Fox Foundation for Parkinson's Research.

**About ProteoTech:** ProteoTech is a private drug development Company founded in 1996 that is a world-leader in therapeutics targeting amyloid diseases. With over 175 patents in its intellectual property estate, ProteoTech is in human clinical trials for its orally active small molecule drug Exebryl-1® for the treatment of mild-to-moderate Alzheimer's disease. The Company is in late-stage pre-clinical development with Synuclere™ for the treatment of Parkinson's disease, and Systebryl™ for the treatment of Systemic Amyloidosis. ProteoTech is also in late stage pre-clinical development for a novel small peptide called PeptiClere™ as a nasal spray for the treatment of Alzheimer's disease. Lastly, ProteoTech is developing a novel small molecule compound for the treatment of amyloidosis associated with type 2 diabetes. For further information, please visit the Company's website at [www.proteotech.com](http://www.proteotech.com) or contact us at [info@proteotech.com](mailto:info@proteotech.com).